Evidence-based personas put behaviour at the centre of customer intelligence

Tern plc

Personas are useful when they help a business understand how people think, decide and act. They are less useful when they simply create a polished version of what a customer might say. That distinction is becoming more important as artificial intelligence makes it easier to generate convincing customer profiles at speed.

Synthetic personas can appear highly realistic. They can answer questions, react to messages and simulate preferences. This makes them useful for quick testing, creative development and early exploration. The risk is that they may reflect what a model assumes a person would say rather than what real people are likely to do.

Evidence-based personas take a different approach. They are built from real-life data and behavioural signals, with synthetic data used to improve and optimise the model. This matters because commercial decisions need more than plausible language. They need insight into behaviour, timing, barriers, motivations and likely action.

Synthetic personas focus mainly on what people say. Evidence-based personas focus on what people do. That makes them more relevant when decisions carry greater risk, when audiences are complex, or when timing matters. In sectors such as healthcare and life sciences, where customer behaviour can be shaped by regulation, professional context and patient need, a stronger evidence base can improve the quality of decision-making.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search